Cancer anorexia: Clinical implications, pathogenesis, and therapeutic strategies

Lancet Oncology

Volumn 4, Issue 11, 2003, Pages 686-694

  Laviano, Alessandro ^a   Meguid, Michael M ^b   Rossi Fanelli, Filippo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; CANNABINOID; CORTICOSTEROID; DEXAMETHASONE; DOCOSAHEXAENOIC ACID; DOPAMINE; DRONABINOL; FLUOXYMESTERONE; GESTAGEN; GHRELIN; ICOSAPENTAENOIC ACID; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NEUROPEPTIDE Y; PENTOXIFYLLINE; PROKINETIC AGENT; SEROTONIN; SURAMIN; THALIDOMIDE; TRYPTOPHAN; TUMOR NECROSIS FACTOR;

ANOREXIA; CANCER PAIN; CANCER PATIENT; CLINICAL TRIAL; CONSTIPATION; CYTOKINE RELEASE; DEEP VEIN THROMBOSIS; DEPRESSION; DIET SUPPLEMENTATION; EATING HABIT; FLUID RETENTION; FOOD INTAKE; HUMAN; HYPOTHALAMUS FUNCTION; MALNUTRITION; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PATIENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; SPOTTING; TUMOR GROWTH; WEIGHT REDUCTION;

EID: 0242691782     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01247-6     Document Type: Review

References (76)

1. Murray MJ, Murray AB. Anorexia of infection as a mechanism of host defense. Am J Clin Nutr 1979; 32: 593-96.
2. Bernstein IL. Taste aversion learning: a contemporary perspective. Nutrition 1999; 15: 229-34.
3. DeWys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69: 491-97.
4. Sutton LM, Demark-Wahnefried W, Clipp EC. Management of terminal cancer in elderly patients. Lancet Oncol 2003; 4: 149-57.
5. Pirovano M, Maltoni M, Nanni O, et al. A new palliative score: a first step for the staging of terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage 1999; 17: 231-39.
6. Maltoni M, Nanni O, Pirovano M, et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage 1999; 17: 240-47.
7. Donnelly S, Walsh D, Rybicki L. The symptoms of advanced cancer: identification of clinical and research priorities by assessment of prevalence and severity. J Palliat Care 1995; 11: 27-32.
8. Bosaeus I, Daneryd P, Lundholm K. Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J Nutr 2002; 132: 3465S-66S.
9. Collins P, Bing C, McCulloch P, Williams G. Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. Br J Cancer 2002; 86: 372-75.
10. Rossi Fanelli F, Muscaritoli M, Cangiano C, et al. The basis for a rational nutritional approach to patients with cancer. In: Abraham NG, Tabilio A, Martelli M, Asano S, Donfrancesco A (Eds) Molecular Biology of Hematopoiesis 6; New York: Kluwer Academic/Plenum Publishers, 1999; 229-34.
11. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2: 862-71.
12. Apolone G, De Carli G, Brunetti M, Garattini S. Health-related quality of life (HR-QOL) and regulatory issues. An assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) recommendations on the use of HR-QOL measures in drug approval. Pharmacoeconomics 2001; 19: 1727-29.
13. Stubbs RJ, Hughes DA, Johnstone AM, et al. The use of visual analogue scales to assess motivation to eat in human subjects: a review of their reliability and validity with an evaluation of new hand-held computerized systems for temporal tracking of appetite ratings. Br J Nutr 2000; 84: 405-15.
14. Rossi Fanelli F, Cangiano C, Ceci F, et al. Plasma tryptophan and anorexia in human cancer. Eur J Cancer Clin Oncol 1986; 22: 89-95.
15. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000; 404: 661-71.
16. Janik JE, Curti BD, Considine RV, et al. Interleukin-1 alpha increases serum leptin concentrations in humans. J Clin Endocrinol Metab 1997; 82: 3084-86.
17. Chance WT, Sheriff S, Moore J, et al. Reciprocal changes in hypothalamic receptor binding and circulating leptin in anorectic tumor-bearing rats. Brain Res 1998; 803: 27-33.
18. Simons JP, Schols AM, Campfield LA, et al. Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci 1997; 93: 273-77.
19. Bing C, Taylor S, Tisdale MJ, Williams G. Cachexia in MAC 16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J Neurochem 2001; 79: 1004-12.
20. Mantovani G, Maccio A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000; 78: 554-61.
21. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
22. Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2001; 2: 551-60.
23. Hanada T, Toshinai K, Kajimura N, et al. Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun 2003; 301: 275-79.
24. Shimizu Y, Nagaya N, Isobe T, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 2003; 9: 774-78.
25. Leal-Cerro A, Soto A, Martinez MA, et al. Influence of cortisol on leptin secretion. Pituitary 2001; 4: 111-16.
26. Kahler A, Zimmermann M, Langhans W. Suppression of hepatic fatty acid oxidation and food intake in men. Nutrition 1999; 15: 819-28.
27. Loftus TM, Jaworsky DE, Frehywot GL, et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000; 288: 2379-81.
28. Rasmussen BB, Holmback UC, Volpi E, et al. Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle. J Clin Invest 2002; 110: 1687-93.
29. Peluso G, Nicolai R, Reda E, et al. Cancer and anticancer therapy-induced modification on metabolism mediated by carnitine system. J Cell Physiol 2000; 182: 339-50.
30. Laviano A, Meguid MM, Renvyle T, et al. Carnitine supplementation accelerates normalization of food intake depressed during TPN. Physiol Behav 1996; 60: 317-20.
31. Laviano A, Meguid MM, Yang Z-J, Gleason JR, Cangiano C, Rossi Fanelli F. Cracking the riddle of cancer anorexia. Nutrition 1996; 12: 706-10.
32. Chance WT, Sheriff S, Kasckow JW, et al. NPY messenger RNA is increased in medial hypothalamus of anorectic tumor-bearing rats. Regul Pept 1998; 75-76: 347-53.
33. Plata-Salaman CR, Ilyin SE, Gayle D. Brain cytokine mRNAs in anorectic rats bearing prostate adenocarcinoma tumor cells. Am J Physiol 1998; 275: 566-73.
34. Makarenko IG, Meguid MM, Gatto L, et al. Decreased NPY innervation of the hypothalamic nuclei in rats with cancer anorexia. Brain Res 2003; 961: 100-08.
35. Marks DL, Butler AA, Turner R, et al. Differential role of melanocortin receptor subtypes in cachexia. Endocrinology 2003; 144: 1513-23.
36. Wisse BE, Frayo RS, Schwartz MW, Cummings DE. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001; 142: 3292-301.
37. Plata-Salaman. Anorexia during acute and chronic disease. Nutrition 1996; 12: 69-78.
38. Opara EI, Laviano A, Meguid MM, Yang Z-J. Correlation between food intake and CSF IL-1α in anorectic tumor bearing rats. Neuro Report 1995; 6: 750-52.
39. Laviano A, Gleason JR, Meguid MM, et al. Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. J Investig Med 2000; 48: 40-48.
40. Cangiano C, Testa U, Muscaritoli M, et al. Cytokines, tryptophan and anorexia in cancer patients before and after surgical tumor ablation. Anticancer Res 1994; 14: 1451-56.
41. Wang W, Lonnroth C, Svanberg E, Lundholm K. Cytokine and cyclooxigenase-2 protein in brain areas of tumor-bearing mice with prostanoid-related anorexia. Cancer Res 2001; 61: 4707-15.
42. Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 1999; 59: 4493-501.
43. Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfluramine. Science 2002; 297: 609-11.
44. Shintani F, Kanba S, Nakaki T, et al. Interleukin-1 beta augments release of norepinephrine, dopamine and serotonin in the rat anterior hypothalamus. J Neurosci 1993; 13: 3574-81.
45. Blaha V, Yang ZJ, Meguid MM, et al. Ventromedial nucleus of hypothalamus is related to the development of cancer-induced anorexia: in vivo microdialysis study. Acta Medica (Hradec Kralove) 1998;41:3-11.
46. Diksic M, Young SN. Study of the brain serotonergic system with labelled α-methyl-L-tryptophan. J Neurochem 2001; 78: 1185-200.
47. Cangiano C, Cascino A, Ceci F, et al. Plasma and CSF tryptophan in cancer anorexia. J Neural Transm Gen Sect 1990; 81: 225-33.
48. Chance WT, von Meyenfeldt M, Fischer JE. Serotonin depletion by 5,7-dihydroxytryptamine or para-chloroamphetamine does not affect cancer anorexia. Pharmacol Biochem Behav 1983; 18: 115-21.
49. Laviano A, Rossi-Fanelli F. Pathogenesis of cancer anorexia. Still doubts after all these years? Nutrition 2003; 19: 67-68.
50. Torelli GF, Meguid MM, Moldawer LL, et al. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol 1999; 277: 850-55.
51. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 2002; 52: 72-91.
52. Maltoni M, Nanni O, Scarpi E, et al. High-dose progestins for the treatment of cancer anorexia-cachexia: a systematic review of randomised clinical trials. Ann Oncol 2001; 12: 289-300.
53. Mantovani G, Maccio A, Lai P, et al. Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncol 1998; 9: 99-106.
54. Jatoi A, Yamashita J, Sloan JA, et al. Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. Support Care Cancer 2002; 10: 71-75.
55. McCarthy HD, Crowder RE, Dryden S, Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neurpoeptide Y concentrations. Eur J Pharmacol 1994; 265: 99-102.
56. Klein TW, Lane B, Newton CA, Friedman H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000; 225: 1-8.
57. Srivastava MD, Srivastava BI, Brouhard B. Delta9-tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998; 40: 179-85.
58. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20: 567-73.
59. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17: 3299-306.
60. Ressel GN. NIH releases statement on managing pain, depression and fatigue in cancer. Am Fam Physician 2003; 67: 423-24.
61. Calder PC. Dietary modifications of inflammation with lipids. Proc Nutr Soc 2002; 61: 345-58.
62. Barber MD, Fearon KC, Tisdale MJ, et al. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer 2001; 40: 118-24.
63. Fearon KC, von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003; 52: 1479-86.
64. Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 2003; 21: 129-34.
65. Jatoi A, Rowland KM, Loprinzi CL, et al. An eicosapentaenioc acid (EPA)-enriched supplement versus megestrol acetate (MA) versus both for patients with cancer-associated wasting: a collaborative effort from the North Central Cancer Treatment Group (NCCTG) and the National Cancer Institute of Canada. Proc Am Soc Clin Oncol 2003; 22: 743 (abstr).
66. Agteresch HJ, Dagnelie PC, van der Gaast A, et al. Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92: 321-28.
67. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003; 9: 47-52.
68. Muscaritoli M, Meguid MM, Beverly JL, et al. Mechanism of early tumor anorexia. J Surg Res 1996; 60: 389-97.
69. Cangiano C, Laviano A, Meguid MM, et al. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J Natl Cancer Inst 1996; 88: 550-52.
70. Hiroshige K, Sonta T, Suda T, et al. Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic hemodialysis. Nephrol Dial Transplant 2001; 16: 1856-62.
71. Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003; 124: 1792-801.
72. Lozano RH, Jofre IS. Novel use of L-DOPA in the treatment of anorexia and asthenia associated with cancer. Palliat Med 2002; 16: 548.
73. Cahlin C, Gelin J, Delbro D, et al. Effect of cyclooxigenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cachexia related to prostanoids. Cancer Res 2000; 60: 1742-49.
74. Squadrito F, Calapai G, Altavilla D, et al. Central serotoninergic system involvement in the anorexia induced by NG-nitro-L-arginine, an inhibitor of nitric oxide synthase. Eur J Pharmacol 1994; 255: 51-55.
75. Lugarini F, Hrupka BJ, Schwartz GJ, et al. A role for cyclooxygenase-2 in lipopolysaccharide-induced anorexia in rats. Am J Phyisiol Regul Integr Comp Physiol 2002; 283: 862-68.
76. Nakamura K, Li YQ, Kaneko T, et al. Prostaglandin E3 receptor Protein in serotonin and catecholamine cell groups: a double immunofluorescence study in the rat brain. Neuroscience 2001; 103: 763-75.